130 related articles for article (PubMed ID: 21765178)
1. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.
Chi KN; Beardsley E; Eigl BJ; Venner P; Hotte SJ; Winquist E; Ko YJ; Sridhar SS; Weber D; Saad F
Ann Oncol; 2012 Jan; 23(1):53-58. PubMed ID: 21765178
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.
Hussain A; DiPaola RS; Baron AD; Higano CS; Tchekmedyian NS; Johri AR
Ann Oncol; 2009 Mar; 20(3):492-7. PubMed ID: 19087985
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Beer TM; Higano CS; Saleh M; Dreicer R; Hudes G; Picus J; Rarick M; Fehrenbacher L; Hannah AL
Invest New Drugs; 2007 Dec; 25(6):565-70. PubMed ID: 17618407
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
Jeske S; Tagawa ST; Olowokure O; Selzer J; Giannakakou P; Nanus DM
Urol Oncol; 2011; 29(6):676-81. PubMed ID: 20451413
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Lee JL; Ahn JH; Choi MK; Kim Y; Hong SW; Lee KH; Jeong IG; Song C; Hong BS; Hong JH; Ahn H
Br J Cancer; 2014 May; 110(10):2472-8. PubMed ID: 24736579
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
12. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Barroso-Sousa R; da Fonseca LG; Souza KT; Chaves AC; Kann AG; de Castro G; Dzik C
Med Oncol; 2015 Jan; 32(1):443. PubMed ID: 25519824
[TBL] [Abstract][Full Text] [Related]
13. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.
Caffo O; Fratino L; Barbieri R; Perin A; Martini T; Sava T; Segati R; Vaccher E; Bernardo Bassan F; Veccia A; Pappagallo G; Galligioni E
Urol Oncol; 2013 Feb; 31(2):180-6. PubMed ID: 21803618
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
[TBL] [Abstract][Full Text] [Related]
19. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
